-
1
-
-
0021688634
-
The neu-oncogene: An erb-B-related gene encoding a 185,000-Mr tumour antigen
-
(1984)
Nature
, vol.312
, Issue.5994
, pp. 513-516
-
-
Schechter, A.L.1
Stern, D.F.2
Vaidyanathan, L.3
Decker, S.J.4
Drebin, J.A.5
Greene, M.I.6
Weinberg, R.A.7
-
2
-
-
0022588467
-
Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor
-
(1986)
Nature
, vol.319
, Issue.6050
, pp. 230-234
-
-
Yamamoto, T.1
Ikawa, S.2
Akiyama, T.3
Semba, K.4
Nomura, N.5
Miyajima, N.6
Saito, T.7
Toyoshima, K.8
-
5
-
-
0028290891
-
The neu oncogene: Signal transduction pathways, transformation mechanisms and evolving therapies
-
(1994)
Oncogene
, vol.9
, Issue.8
, pp. 2109-2123
-
-
Dougall, W.C.1
Qian, X.2
Peterson, N.C.3
Miller, M.J.4
Samanta, A.5
Greene, M.I.6
-
19
-
-
0026793986
-
Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer
-
(1992)
Hum Pathol
, vol.23
, pp. 974-979
-
-
Allred, D.C.1
Clark, G.M.2
Molina, R.3
Tandon, A.K.4
Schnitt, S.J.5
Gilchrist, K.W.6
Osborne, C.K.7
Tormey, D.C.8
McGuire, W.L.9
-
20
-
-
0033868761
-
Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: An immunohistochemical study
-
(2000)
Ann Clin Lab Sci
, vol.30
, pp. 259-265
-
-
Masood, S.1
Bui, M.M.2
-
22
-
-
0032850677
-
Multinational study of the efficacy and safety of humanized anti-HER-2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
-
(1999)
J Clin Oncol
, vol.17
, pp. 2639-2648
-
-
Cobleigh, M.A.1
Vogel, C.L.2
Tripathy, D.3
Robert, N.J.4
Scholl, S.5
Fehrenbacher, L.6
Wolter, J.M.7
Paton, V.8
Shak, S.9
Lieberman, G.10
Slamon, D.J.11
-
25
-
-
17944379992
-
Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases
-
(2000)
Am J Clin Pathol
, vol.113
, pp. 675-682
-
-
Gancberg, D.1
Lespagnard, L.2
Rouas, G.3
Paesmans, M.4
Piccart, M.5
Di Leo, A.6
Nogaret, J.M.7
Hertens, D.8
Verhest, A.9
Larsimont, D.10
-
30
-
-
0028997307
-
HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-dependent growth in human breast cancer cell
-
(1995)
Oncogene
, vol.10
, pp. 2435-2446
-
-
Pietras, R.J.1
Arboleda, J.2
Reese, D.M.3
Wongvipat, N.4
Pegram, M.D.5
Ramos, L.6
Gormon, C.M.7
Parker, M.G.8
Sliwkoski, M.X.9
Slamon, D.J.10
-
33
-
-
0028301750
-
Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer
-
(1994)
Cancer
, vol.73
, pp. 2359-2365
-
-
Tetu, B.1
Brisson, J.2
-
35
-
-
0004654306
-
ER, PgR, c-erbB2 and EGFr in patients randomised to adjuvant tamoxifen or no treatment associations with treatment benefit
-
Abstract 102
-
(1999)
Sixth Nottingham International Breast Cancer Conference
, vol.18
-
-
Dowsett, M.1
Houghton, J.2
Baum, M.3
Salter, J.4
A'Hern, T.5
Iden, C.6
Fardon, J.7
-
36
-
-
0001073075
-
Lack of interaction of tamoxifen (T) use and erbB-2/HER-2/neu (H) expression in CALGB 8541: A randomised adjuvant trial of three different doses of cyclophosphamide, doxorubicin and fluorouracil (CAF) in node-positive primary breast cancer (BC)
-
Abstract 256
-
(1999)
Proc ASCO
, vol.18
-
-
Muss, H.1
Berry, D.2
Thor, E.3
Liu, S.4
Edgerton, D.5
Budman, K.6
Wood, W.7
Henderson, C.8
Cirrinclone, C.9
Hayes, D.10
Barcos, M.11
Norton, L.12
-
42
-
-
0031699459
-
C-erbB2 expression predicts response to pre-operative chemotherapy for locally advanced breast cancer
-
(1998)
Anticancer Res
, vol.18
, pp. 3695-3698
-
-
Willsher, P.C.1
Pinder, S.E.2
Gee, J.M.3
Ellis, I.O.4
Chan, S.Y.5
Nicholson, R.I.6
Blamey, R.W.7
Robertson, J.F.8
-
44
-
-
0026576399
-
HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma
-
(1992)
J Clin Oncology
, vol.10
, Issue.4
, pp. 599-605
-
-
Allred, D.C.1
Clark, G.M.2
Tandon, A.K.3
Molina, R.4
Tormey, D.C.5
Osborne, C.K.6
Gilchrist, K.W.7
Mansour, E.G.8
Abeloff, M.9
Eudey, L.10
-
45
-
-
0026625217
-
Prognostic importance of c-erbB-2 expression in breast cancer
-
International (Ludwig) Breast Cancer Study Group [see comments]
-
(1992)
J Clin Oncol
, vol.10
, Issue.7
, pp. 1049-1056
-
-
Gusterson, B.A.1
Gelber, R.D.2
Goldhirsch, A.3
Price, K.N.4
Save-Soderborgh, J.5
Anbazhagan, R.6
Styles, J.7
Rudenstam, C.M.8
Golouh, R.9
Reed, R.10
-
47
-
-
0029591205
-
c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer
-
(1995)
Eur J Cancer
, vol.31 A
, Issue.13-14
, pp. 2185-2190
-
-
Stal, O.1
Sullivan, S.2
Wingren, S.3
Skoog, L.4
Rutqvist, L.E.5
Carstensen, J.M.6
Nordenskjold, B.7
-
48
-
-
0031930148
-
HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group study
-
(1998)
Clin Cancer Res
, vol.4
, Issue.1
, pp. 7-12
-
-
Elledge, R.M.1
Green, S.2
Ciocca, D.3
Pugh, R.4
Allred, D.C.5
Clark, G.M.6
Hill, J.7
Ravdin, P.8
O'Sullivan, J.9
Martino, S.10
Osborne, C.K.11
-
49
-
-
0032538050
-
erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
-
(1998)
J Natl Cancer Inst
, vol.90
, Issue.18
, pp. 1346-1360
-
-
Thor, A.D.1
Berry, D.A.2
Budman, D.R.3
Muss, H.B.4
Kute, T.5
Henderson, I.C.6
Barcos, M.7
Cirrincione, C.8
Edgerton, S.9
Allred, C.10
Norton, L.11
Liu, E.T.12
-
50
-
-
0033993447
-
High local recurrence risk after breast-conserving therapy in node-negative premenopausal breast cancer patients is greatly reduced by one course of perioperative chemotherapy: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study
-
(2000)
J Clin Oncol
, vol.18
, Issue.5
, pp. 1075-1083
-
-
Elkhuizen, P.H.1
Van Slooten, H.J.2
Clahsen, P.C.3
Hermans, J.4
Van de Velde, C.J.5
Van den Broek, L.C.6
Van de Vijver, M.J.7
-
51
-
-
0032548879
-
No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer
-
(1998)
Int J Cancer
, vol.79
, Issue.1
, pp. 27-33
-
-
Rozan, S.1
Vincent-Salomon, A.2
Zafrani, B.3
Validire, P.4
De Cremoux, P.5
Bernoux, A.6
Nieruchalski, M.7
Fourquet, A.8
Clough, K.9
Dieras, V.10
Pouillart, P.11
Sastre-Garau, X.12
-
52
-
-
0004652721
-
-
Data Sheet Summary of Product Characteristics. 'Herceptin' Summary of Product Characteristics. Roche Registration Ltd, 2000
-
-
-
-
56
-
-
0000405942
-
Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: A randomised multinational controlled phase III trial
-
(1998)
Proc Am Soc Clin Oncol
, vol.17
-
-
Slamon, D.1
Leyland-Jones, S.2
Shak, S.3
Paton, V.4
Bajamonde, A.5
Fleming, T.6
Eiermann, W.7
Wolter, J.8
Baselga, J.9
Norton, L.10
-
57
-
-
0000212829
-
Overall survival (OS) advantage to simultaneous chemotherapy plus the humanized anti-HER2 monoclonal antibody Herceptin in HER2-overexpressing metastatic breast cancer
-
(1999)
35th Am Soc Clin Oncol
, vol.18
, pp. 127
-
-
Norton, L.1
Slamon, D.2
Leyland-Jones, B.3
Wolter, J.4
Fleming, T.5
Eirmann, W.6
Baselga, J.7
Mendelsohn, J.8
Bajamonde, A.9
Ash, M.10
Shak, S.11
|